TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Today

Rule Breakers article.

TMFBiologyFool published an update. 12:42 AM

Rule Breakers article.

TMFBiologyFool published an update. 12:14 AM

Yesterday

NL

Article

TMFBiologyFool published an article 9:00 PM

Still Waiting for Profitability at Genomic Health

Prospects for reimbursement are improving.

NL

Article

TMFBiologyFool published an article 5:46 PM

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

NL

Article

TMFBiologyFool published an article 4:40 PM

Momenta Has Momentum

The launch of Glatopa is off to a good start and the biotech has more drugs in the works.

Rule Breakers Boards Post

TMFBiologyFool replied to the Rule Breakers boards. 1:36 PM

Rule Breakers article.

TMFBiologyFool published an update. 1:53 AM

Mon Aug 3

NL

Article

TMFBiologyFool published an article 9:00 PM

BioMarin Pharmaceuticals: Lumpy Sales Strike Again

The biotech beats on revenue, but it's where the sales came from that made for a solid-but-not-outstanding quarter.

Rule Breakers Boards Post

TMFBiologyFool posted to the Rule Breakers boards. 12:51 PM

Fri Jul 31

Rule Breakers article.

TMFBiologyFool published an update. 9:03 PM

NL

Article

TMFBiologyFool published an article 8:35 PM

3 Things to Watch as Genomic Health Reports Earnings

Test usage, reimbursement, and the move into liquid biopsy are all important for the cancer-test company.

Rule Breakers article.

TMFBiologyFool published an update. 4:05 PM

NL

Article

TMFBiologyFool published an article 4:00 PM

ImmunoGen: Back to a Development-Stage Biotech

With the biotech no longer collecting Kadcyla royalties, the pipeline becomes the focus of the release of quarterly earnings.

Rule Breakers article.

TMFBiologyFool published an update. 9:34 AM

Thu Jul 30

NL

Article

TMFBiologyFool published an article 11:40 PM

Still Profitless in Seattle Genetics

But a growth opportunity is around the corner.

Income Investor article.

TMFBiologyFool published an update. 8:34 PM

NL

Article

TMFBiologyFool published an article 8:01 PM

The Tale of Two Teva Pharmaceuticals

Revenue down, earnings up. At least it wasn't the other way around.

NL

Article

TMFBiologyFool published an article 3:40 PM

An Animal of a Quarter for IDEXX

The animal-testing company posts substantial growth at constant currencies.

Stock Advisor article.

TMFBiologyFool published an update. 2:11 PM

Stock Advisor article.

TMFBiologyFool published an update. 1:51 PM

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 95.33
Player Rank 3511 out of 75199
Score 1344.16
Score Change Today -67.83
Accuracy 66.67%
Active Picks 73
Total Picks 215
Best Pick ALKS (+407.63)
Worst Pick INCY (-1070.87)
Average Score per Pick 6.25
Charms Earned 10
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Big red star, 1000 posts CAPS All Star
Board Posts 1019
Recs Received 1180
People who have rec'd these posts 460
Recs to Posts Ratio (last 30 days) 4.60
Threads Started 104
Threads Started Percentage 10.21 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 49.85 %
Show TMFBiologyFool’s 10 Latest Posts